Status:
COMPLETED
Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Prostate Cancer
Eligibility:
MALE
40+ years
Phase:
NA
Brief Summary
We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will ende...
Detailed Description
The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites ...
Eligibility Criteria
Inclusion
- Histologically verified prostate cancer
- Patient has opted for surgery
- Low risk prostate cancer PSA \<1 0, Gleason \< 7, Stage \< T2b
- No contraindication to MR scanning
- No prior history of malignancy
- Fit for surgery
Exclusion
- Nonbiopsied lesion
- Intermediate or high risk prostate cancer
- Unfit for surgery
- Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00310479
Start Date
June 1 2006
End Date
March 1 2008
Last Update
February 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2